Previous close | 11.50 |
Open | 11.50 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 10.70 - 11.50 |
52-week range | 10.29 - 11.75 |
Volume | |
Avg. volume | 818 |
Market cap | 89.433M |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 73.00 |
EPS (TTM) | 0.15 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB), a special purpose acquisition company (“Atlantic Coastal”), today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange C
Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition corporation, announced that Atlantic Coastal Acquisition Management II LLC, the Company's initial public offering sponsor (the "Sponsor"), has deposited $80,000 into the Company's trust account (the "Trust Account) in order to extend the period of time that the Company has to complete a business combination for an additional one (1) month period, from October 19, 2023 to November 19, 2023. In exch
Atlantic Coastal Acquisition Corp. (NASDAQ: ACAH) (the "Company"), a special purpose acquisition corporation, today announced that it filed a Schedule 14A Definitive Proxy Statement on September 6, 2023 (the "Definitive Proxy Statement") in connection with a special meeting (the "Special Meeting") to extend the amount of time the Company has to consummate a business combination (the "Extension"). This filing follows the Company's Schedule 14A Preliminary Proxy Statement that was filed on August